Skip to main content
Retour
BLFS logo

BioLife Solutions, Inc.

Qualité des données : 100%
BLFS
NASDAQ Healthcare Medical - Instruments & Supplies
19,17 €
▲ 0,32 € (1,70%)
Cap. Boursière : 925,91M
Fourchette du Jour
18,91 € 19,50 €
Fourchette 52 Semaines
17,86 € 29,62 €
Volume
443 257
Moyenne 50J / 200J
22,25 € / 24,03 €
Clôture Précédente
18,85 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -76,3 0,4
P/B 2,5 2,9
ROE % -3,4 3,7
Net Margin % -12,6 3,9
Rev Growth 5Y % -5,2 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
33,00 € +72.1%
Low: 32,00 € High: 34,00 €
P/E Prévisionnel
129,7
BPA Prévisionnel
0,15 €
Croissance BPA (est.)
+0,0%
CA Est.
110 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,81 €
1,77 € – 1,85 €
240 M 1
FY2029 1,31 €
1,28 € – 1,34 €
200 M 1
FY2028 0,88 €
0,86 € – 0,90 €
170 M 1

Points Clés

Revenue declined -5,21% annually over 5 years
Debt/Equity of 0,05 — conservative balance sheet
Generating 10,64M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 22,18%
Capital efficient — spends only 9,85% of revenue on capex

Croissance

Revenue Growth (5Y)
-5,21%
Revenue (1Y)16,97%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-3,37%
ROIC-2,33%
Net Margin-12,61%
Op. Margin-12,61%

Sécurité

Debt / Equity
0,05
Current Ratio5,23
Interest Coverage-4,48

Valorisation

P/E Ratio
-76,33
P/B Ratio2,49
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16,97% Revenue Growth (3Y) 12,62%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -5,21% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 96,21M Net Income (TTM) -12,13M
ROE -3,37% ROA -2,99%
Gross Margin 64,56% Operating Margin -12,61%
Net Margin -12,61% Free Cash Flow (TTM) 10,64M
ROIC -2,33% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,05 Current Ratio 5,23
Interest Coverage -4,48 Dividend Yield 0,00%
Valuation
P/E Ratio -76,33 P/B Ratio 2,49
P/S Ratio 9,62 PEG Ratio 2,20
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 925,91M Enterprise Value 910,77M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 96,21M 82,25M 75,86M 76,24M 119,16M
Net Income -12,13M -20,18M -66,43M -139,81M -8,91M
EPS (Diluted) -0,25 -0,44 -1,52 -3,29 -0,23
Gross Profit 62,12M 53,67M 46,75M 46,91M 28,85M
Operating Income -12,13M -7,13M -23,44M -5,92M -35,16M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 405,88M 399,49M 412,71M 450,23M 552,60M
Total Liabilities 34,00M 50,58M 75,05M 86,04M 76,24M
Shareholders' Equity 371,89M 348,91M 337,66M 364,19M 480,75M
Total Debt 17,90M 30,17M 33,83M 43,71M 26,88M
Cash & Equivalents 33,04M 95,39M 27,90M 19,44M 69,87M
Current Assets 120,18M 148,76M 120,60M 138,45M 125,86M
Current Liabilities 22,98M 32,73M 42,18M 44,58M 42,70M